The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Am J Psychiatry 164:524-a, March 2007
doi: 10.1176/appi.ajp.164.3.524-a
© 2007 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by McGRATH, P. J.
* Articles by RUSH, A. J.
* Search for Related Content
PubMed
* Articles by McGRATH, P. J.
* Articles by RUSH, A. J.
Related Collections
* Antidepressants

Letter to the Editor

Dr. McGrath and Colleagues Reply

PATRICK J. McGRATH, M.D., JONATHAN W. STEWART, M.D., MAURIZIO FAVA, M.D., MADHUKAR H. TRIVEDI, M.D., STEPHEN R. WISNIEWSKI, Ph.D., ANDREW A. NIERENBERG, M.D., MICHAEL E. THASE, M.D., LORI DAVIS, M.D., MELANIE M. BIGGS, Ph.D., KATHY SHORES-WILSON, Ph.D., JAMES F. LUTHER, M.A., DIANE WARDEN, Ph.D., M.B.A., and A. JOHN RUSH, M.D.
New York, N.Y.

To The Editor: We agree with the important point raised by Drs. Nolen et al. Their landmark studies, cited in our paper, clearly suggest that doses of tranylcypromine higher than those approved by the Food and Drug Administration (FDA) in the United States show substantial efficacy in treatment-resistant depression. Because STAR*D decided to use dosages only up to the FDA recommended maximum, STAR*D was unable to test the effectiveness of the doses Nolen et al. and others have used for treatment-resistant depression. As indicated in our article, even the maximum allowable dose was infrequently used. The low likelihood of remission in STAR*D patients treated with tranylcypromine, together with its low dosing and poor tolerance, support our conclusion that tranylcypromine is not a treatment clinicians in most practice settings are likely to use optimally or successfully. Nevertheless, we fully agree with Nolen et al. that a vigorous trial of an MAOI should be considered for depressed patients not responsive to multiple other antidepressant trials. However, the experience of STAR*D suggests that tranylcypromine and other MAOI treatment may be better handled by a psychopharmacology specialist who is knowledgeable about these agents, and who is aware that higher than recommended doses of tranylcypromine may be very effective for select patients.





This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by McGRATH, P. J.
* Articles by RUSH, A. J.
* Search for Related Content
PubMed
* Articles by McGRATH, P. J.
* Articles by RUSH, A. J.
Related Collections
* Antidepressants


Get information about faster international access.

Privacy Policy

Copyright © 2007 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org